Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q2 2025 value amounting to -$40.6 million.

  • KalVista Pharmaceuticals' Free Cash Flow fell 16688.14% to -$40.6 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$120.6 million, marking a year-over-year decrease of 3457.02%. This contributed to the annual value of -$153.4 million for FY2025, which is 7114.65% down from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Free Cash Flow stood at -$40.6 million for Q2 2025, which was down 16688.14% from -$39.7 million recorded in Q4 2024.
  • KalVista Pharmaceuticals' 5-year Free Cash Flow high stood at -$15.2 million for Q2 2024, and its period low was -$40.6 million during Q2 2025.
  • Its 3-year average for Free Cash Flow is -$30.0 million, with a median of -$27.7 million in 2024.
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Free Cash Flow tumbled by 5067.32% in 2024, and later tumbled by 16688.14% in 2025.
  • Quarter analysis of 3 years shows KalVista Pharmaceuticals' Free Cash Flow stood at -$20.0 million in 2023, then tumbled by 98.46% to -$39.7 million in 2024, then dropped by 2.17% to -$40.6 million in 2025.
  • Its last three reported values are -$40.6 million in Q2 2025, -$39.7 million for Q4 2024, and -$40.3 million during Q3 2024.